investment

CytomX Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation

Seeking Alpha

1 min read

0 likes

⚡ Quantum Brief

CytomX Therapeutics reported a Q4 2025 earnings per share loss of $0.22, missing analyst estimates by $0.13, reflecting continued financial struggles. Revenue plummeted 98.26% year-over-year to $663,000, falling $6.66 million short of projections, signaling steep operational challenges. The earnings call slide deck, released March 2026, accompanied the company’s Q4 results, highlighting key financial and strategic updates for stakeholders. No major breakthroughs or pipeline advancements were emphasized, suggesting limited near-term catalysts for recovery or investor confidence. The sharp revenue decline underscores broader industry pressures, raising questions about CytomX’s long-term viability and funding sustainability.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts159K FollowersFollow5ShareSaveCommentsQ4: 2026-03-16 Earnings SummaryInsightsTranscript InsightsTranscriptPR10-KEPS of -$0.22 misses by $0.13 | Revenue of $663.00K (-98.26% Y/Y) misses by $6.66MThe following slide deck was published by CytomX Therapeutics, Inc. in conjunction with their 2025 Q4 earnings call. This article was written bySA Transcripts159K FollowersFollowSeeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.